Evidence map›Paper›PMID 30232196›Full record

ArticleGenome research2018

Targeted genome fragmentation with CRISPR/Cas9 enables fast and efficient enrichment of small genomic regions and ultra-accurate sequencing with low DNA input (CRISPR-DS).

Daniela Nachmanson, Shenyi Lian, Elizabeth K Schmidt, Michael J Hipp, Kathryn T Baker, Yuezheng Zhang, Maria Tretiakova, Kaitlyn Loubet-Senear, Brendan F Kohrn, Jesse J Salk and 2 more

Abstract readComparative Study
In one paragraph

Article in Genome research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. De novo rates of aProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. CRISPR in cancer biology and therapy.Nature reviews. Cancer · 2022
    Review
  18. Article
  19. Article
  20. PolyG-DS: An ultrasensitive polyguanine tract-profiling method to detect clonal expansions and trace cell lineage.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Daniela NachmansonDepartment of Pathology, University of Washington, Seattle, Washington 98195, USA.
Shenyi LianDepartment of Pathology, University of Washington, Seattle, Washington 98195, USA.
Elizabeth K SchmidtDepartment of Pathology, University of Washington, Seattle, Washington 98195, USA.
Michael J HippDepartment of Pathology, University of Washington, Seattle, Washington 98195, USA.
Kathryn T BakerDepartment of Pathology, University of Washington, Seattle, Washington 98195, USA.
Yuezheng ZhangDepartment of Pathology, University of Washington, Seattle, Washington 98195, USA.
Maria TretiakovaDepartment of Pathology, University of Washington, Seattle, Washington 98195, USA.
Kaitlyn Loubet-SenearDepartment of Pathology, University of Washington, Seattle, Washington 98195, USA.
Brendan F KohrnDepartment of Pathology, University of Washington, Seattle, Washington 98195, USA.
Jesse J SalkDepartment of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington 98195, USA.
Scott R Kennedy *Department of Pathology, University of Washington, Seattle, Washington 98195, USA.
Rosa Ana Risques *Department of Pathology, University of Washington, Seattle, Washington 98195, USA.

Funding

TRAINING IN CANCER BIOLOGY &TRANSPLANTATIONT32CA009515 · NCI · UNIVERSITY OF WASHINGTON · PI NANCY ELLEN DAVIDSON, Effie W Petersdorf · 1985 to 2026
$16.2M
Clonally Expanded Mutations Identify Cancer Precursors in Chronic InflammationR01CA160674 · NCI · UNIVERSITY OF WASHINGTON · PI BRENTNALL, TERESA A, LOEB, LAWRENCE A · 2012 to 2016
$2.8M
Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex SequencingR44CA221426 · NCI · TWINSTRAND BIOSCIENCES, INC. · PI SALK, JESSE J · 2017 to 2020
$2.3M
Mitochondrial biomarkers for early detection of cancer in ulcerative colitisR01CA181308 · NCI · UNIVERSITY OF WASHINGTON · PI RISQUES, ROSA ANA · 2014 to 2018
$1.4M
NCI NIH HHS R01 CA160674NCI NIH HHS R01 CA181308NCI NIH HHS R44 CA221426NCI NIH HHS T32 CA009515
6 · The paper itself

Abstract

Next-generation sequencing methods suffer from low recovery, uneven coverage, and false mutations. DNA fragmentation by sonication is a major contributor to these problems because it produces randomly sized fragments, PCR amplification bias, and end artifacts. In addition, oligonucleotide-based hybridization capture, a common target enrichment method, has limited efficiency for small genomic regions, contributing to low recovery. This becomes a critical problem in clinical applications, which value cost-effective approaches focused on the sequencing of small gene panels. To address these issues, we developed a targeted genome fragmentation approach based on CRISPR/Cas9 digestion that produces DNA fragments of similar length. These fragments can be enriched by a simple size selection, resulting in targeted enrichment of up to approximately 49,000-fold. Additionally, homogenous length fragments significantly reduce PCR amplification bias and maximize read usability. We combined this novel target enrichment approach with Duplex Sequencing, which uses double-strand molecular tagging to correct for sequencing errors. The approach, termed CRISPR-DS, enables efficient target enrichment of small genomic regions, even coverage, ultra-accurate sequencing, and reduced DNA input. As proof of principle, we applied CRISPR-DS to the sequencing of the exonic regions of

Indexed as

CRISPR-Cas SystemsDNADNA FragmentationFemaleHigh-Throughput Nucleotide SequencingHumansOvarian NeoplasmsSequence Analysis, DNATumor Suppressor Protein p53DNATP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID30232196
PMCPMC6169890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.